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Abstract
Carboplatin (CRB) possesses superior anticancer effect in cervical cancer cells with lower incidence of side effects
compared to that of cisplatin. However, CRB suffers from severe side effects due to undesirable tissue distributions
which contribute to the low therapeutic efficacy. Here, we report a unique folic acid-conjugated chitosan-coated
poly(D-L-lactideco-glycolide) (PLGA) nanoparticles (FPCC) prepared for the selective delivery of carboplatin to the
cervical cancer cells. The particles were nanosized and spherical shaped with size less than <200 nm. The presence
of protective chitosan layer controlled the overall release rate of CRB from chitosan-coated PLGA nanoparticles
(PCC) and FPCC. FPCC displayed a higher cellular uptake capacity in HeLa cells than compared to non-targeted
nanoparticles. Selective uptake of FPCC was due to an interaction of folic acid (FA) with the folate receptors alpha
(FRs-α) which is overexpressed on the HeLa and promoted active targeting. These results indicated that FPCC had a
specific affinity for the cancerous, HeLa cells owing to ligand-receptor (FA-FR-α) recognition. Consistently, FPCC
showed superior cytotoxic effect than any other formulations. The IC50 (concentration of the drug required to kill
50 % of the cells) value of FPCC was 0.65 μg/ml while it was 1.08, 1.56, and 2.35 μg/ml for PCC, PLGA NP, and free
CRB, respectively. Consistent with the cytotoxicity assay, FPCC induced higher fraction of early as well as late
apoptosis cells. Especially, FPCC induced nearly 45 % of early apoptosis cells and more than 35 % in late apoptosis.
Therefore, we propose that folate-conjugated nanoparticles might have potential applications in cervical cancer
therapy.
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Background
Cervical cancer is the third most common cancer in
women and caused by human papillomavirus (HPV) [1].
Although advanced cancer screening and vaccine re-
duced the mortality rate of patients due to cervical can-
cers in developed countries, it is still the leading cause
of cancer-related death in developing countries like
China [2, 3]. There are many treatment options for cer-
vical cancers including surgery, chemotherapy, and
radiotherapy; however, none was effective in completing
curing the cancers and often recurrence was seen.
Recently, two prophylactic HPV vaccines (Gardasil and
Cervarix) were approved for the HPV-associated dis-
eases. However, these vaccines are effective only in ado-
lescents with no history of previous HPV infection and
have not shown any therapeutic effects against current
HPV infections or cervical cancers [4, 5]. Therefore,
there is an urgent need to design new approaches and
methods to treat cervical cancers.
In this regard, platinum-based drugs (carboplatin and
cisplatin) are indicated in the treatment of multiple cancers
including cervical cancers [6]. Carboplatin (CRB) (cis-di-
amine (1,1-cyclobutanedicarboxylato)-platinum (II)), a
cisplatin analog, is reported to possess superior anti-
cancer effect in cancer cells and lower incidence of
side effects compared to that of cisplatin [7, 8]. Des-
pite the potential anticancer effect, CRB suffers from
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severe myelosuppression, thrombocytopenia, and leuco-
penia (in older patients). Furthermore, lower cellular
uptake of CRB in cancer cells also contributes to the low
therapeutic efficacy [9, 10]. Therefore, it is important to
protect the CRB in the blood circulation, and exposure to
cancer cells is prolonged to achieve maximum cytotoxic
activity. In order to overcome all the drawbacks, we have
designed a targeted delivery system which is specific to
the cervical cancer cell and thereby increase the thera-
peutic effect and decrease the side effects.
Ligand conjugation to the carrier system could en-
hance the specific delivery of drug to the cancer cells.
Generally, functionalized nanosystem could target the
molecular receptors which are overexpressed in the
tumor cells and release its active payload [11]. Recently,
polymeric nanoparticles ranging between 100 and
200 nm have gained significant attention due to its high
drug-loading capacity, non-immunogenicity, and bio-
degradability [12, 13]. In the present study, poly(D-L-lacti-
deco-glycolide) (PLGA) polymer has been selected to
incorporate CRB. The excellent features of PLGA NP
include prolonged systemic circulation, effective intracellu-
lar delivery, excellent biocompatibility, and biodegradabil-
ity. However, drug leakage in the blood circulation and
negative charge on the particle surface might diminish the
activity of incorporate drug [14–16]. Therefore, chitosan
(CS) which is a naturally occurring biodegradable polymer
was coated on the PLGA surface [17]. The high zeta poten-
tial of chitosan (positively charged) enables the easy surface
modification of PLGA NP via electrostatic interactions
[18]. The surface modification with chitosan presents many
advantages including protection of active drug in the sys-
temic circulation, as a stealth protective layer, and increases
the intracellular uptake (due to the interaction of positively
charged particle with negatively charged cell membrane)
[19–21].
Among various low and high molecular weight ligands
(folate, mannose, transferrin), folic acid which is overex-
pressed in cervical cancer cells (HeLa), was selected to
deliver the CRB to the tumor region [22]. Functional fol-
ate receptors alpha (FRs-α) are highly overexpressed in
cervical cancer cells [23]. FR-α is a glycosyl phosphatidyl
inositol (GPI)-linked protein which is present in the ap-
ical region of normal cells which is not exposed to the
blood circulation, whereas in case of cancer cells, it is
exposed to the blood circulation and therefore, folate-
conjugated nanoparticles internalized with high affinity
(receptor-mediated endocytosis) [24, 25]. There are sev-
eral reports regarding the intracellular delivery of folate-
conjugated nanopharmaceuticals in FR-α overexpressed
cancer cells [26].
Carboplatin (CRB) is an excellent drug to treat cervical
cancers; however, it leads to severe side effects mainly
due to the irrational and undesirable biodistribution.
Additionally, abnormal extracellular matrix offers accel-
erated frictional resistance of the anticancer drug pene-
tration. Therefore, active targeting of CRB to the cancer
cells increase the concentration of drug on the tumor
site while it minimized the associated side effects. In the
present study, therefore, we have designed a unique folic
acid-conjugated chitosan-coated PLGA nanoparticle
(FPCC). The high zeta potential of chitosan (positively
charged) enables the easy surface modification of PLGA
NP via electrostatic interactions (Fig. 1). FA over the
surface of nanoparticles remarkably influenced the
therapeutic efficacy of encased cytotoxic drug.
Therefore, in the present investigation, folate-grafted
chitosan/PLGA nanoparticle was prepared to deliver
Fig. 1 Schematic presentation of preparation of folic acid-conjugated chitosan-coated PLGA nanoparticles. Chitosan-folic acid conjugation was
separately depicted
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carboplatin to the FR-α overexpressed HeLa cervical
cancer cells. The physicochemical characteristics of opti-
mized nanoformulations were studied by dynamic light
scattering (DLS) technique. In vitro drug release profile
was investigated for different formulations. Cellular up-
take efficiency of targeted and non-targeted nanoparticles
was investigated to prove the targetability of folate-grafted
carrier. Consistently, cytotoxicity assay and apoptosis ana-
lysis were carried out to show the superior anticancer
effect of folate-grafted nanocarrier.
Methods
Materials
Carboplatin, folic acid, PLGA 50:50, MW 40,000–
75,000 Da, dexamethasone (DXM) ≥98 %, chitosan (CS)
75–85 % deacetylated, average MW 50,000 Da, and all
other chemicals were purchased from Sigma-Aldrich,
China.
Preparation of Folic Acid-Conjugated Chitosan-Coated
PLGA Nanoparticles
One hundred milligrams of PLGA and 25 mg of CRB were
dissolved in 5 ml of dimethylsulfoxide (DMSO). The solu-
tion was added dropwise into 25 ml of a selected non-
solvent of the polymer (H2O). The solution was stirred for
3 h until all the organic solvent evaporated. Subsequently,
titrated volume of 1 % chitosan solution was added to the
PLGA solution under constant stirring at room
temperature. The suspension was then centrifuged at
10,000 rpm for 30 min at 4 °C, and the supernatant was
removed. The pellet was then washed twice with deion-
ized water and recovered by centrifugation.
Separately, chitosan-folic acid (CH-FA) was synthesized
by chemical conjugation. Briefly, 10 mg of folic acid (FA)
was added to a mixture of 1-(3-dimethylaminopropyl)-3-
ethyl carbodiimide hydrochloride (EDAC.HCl) and N-hy-
droxy succinimide (NHS) (10:25 mg) prepared in 10 mL
of DMSO. The activation was carried out under inert
atmosphere for 30 min. The activated FA solution was
then added dropwise to the chitosan solution. The prod-
uct was filtered and dried. The amount of CRB entrapped
in the nanoparticle was evaluated by filtration method.
The drug-loaded nanoparticle dispersion was filtered, and
the supernatant was subject to ICP-MS method to evalu-
ate the entrapment efficiency and loading capacity in the
nanoparticles.
Particle Size and Zeta Potential Analysis
The average particle diameter, particle size distribution, and
surface charge were determined using dynamic light scat-
tering (DLS) technique by Zetasizer Nano ZS (Malvern,
UK) at 25 °C. The formulations were suitably diluted before
the experiment.
Transmission Electron Microscopy (TEM) Observation
The morphology and size of the particles were observed
using transmission electron microscopy (Jeol JEM1200EX,
Tokyo, Japan) operated at an accelerated voltage of 80 kV.
The samples were negatively stained with 2 % PTA and
then placed a drop in the copper grid, air dried, and
observed under microscope.
In Vitro Release Study
CRB-loaded PLGA NP, PCC, and FPCC was dissolved in
2 ml of buffer to form a suspension and then transferred
to dialysis membrane (Spectra/Por 6, MWCO 3000,
Spectrum Laboratories, Inc., TX, USA). The bag was
closed and immersed in 20 ml the release medium and
put in an orbital shaker set at 100 rpm at 37 °C. From time
to time, 1 ml of the release medium was withdrawn and
replaced with equal amount of fresh buffer. The amount
of drug released was determined by ICP-MS method.
Cell Culture
Human cervical carcinoma cell line HeLa cells were cul-
tured in DMEM supplemented with 10 % fetal bovine
serum (FBS), 100 U/mL penicillin, and 100 mg/mL
streptomycin at 37 °C in a humidified atmosphere con-
taining 5 % carbon dioxide.
Cellular Uptake Analysis
The cellular uptake of nanoparticles in HeLa cells was
determined by fluorescence method. In brief, 2 × 104
cells were seeded in a 96-well plate and incubated over-
night. The medium was removed and treated with fresh
medium containing PLGA NP, PCC, and FPCC. To
study the effect of targeted and non-targeted nanoparti-
cles, coumarin-6 was used as a fluorescent probe. The
formulations were incubated for 1, 2, and 4 h and then
washed with PBS. Cells were lysed with the help of lysis
buffer (1 % Triton-X in 0.2 N NaOH), and the fluores-
cent intensity of probe was evaluated by means of
microplate reader (GENios, Tecan, Switzerland) with
excitation wavelength at 430 nm and emission wave-
length at 485 nm.
Cellular Uptake Imaging
The qualitative cellular uptake of nanoparticles in HeLa
was evaluated using a confocal laser scanning microscope
(Olympus Fluoview FV-1000, Tokyo, Japan). For this pur-
pose, cells were seeded in six-well plate at a seeding dens-
ity of 2 × 105 cells and incubated for 24 h. The cells were
then exposed with the coumarin-6-loaded formulations
and incubated for 2 h. The cells were washed three times
with cold PBS, fixed by cold methanol for 20 min, and fur-
ther washed twice with PBS. The cells were then viewed
under CLSM microscope.
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Cytotoxicity Assay
The in vitro cytotoxicity assay of free CRB, PLGA NP,
PCC, and FPCC was studied in HeLa cancer cells by
MTT assay protocol. For this purpose, 1 × 104 cells
which were in the logarithmic phase of growth were
seeded in each well of 96-well plate. As mentioned
above, DMEM supplemented with 10 % FBS and 1 %
antibiotic was used as a growth media. When the conflu-
ence of cells reaches 85 %, old media was removed and
replaced with new media containing individual formula-
tions in a dose-dependent manner and incubated for
24 h. After that, 10 μl of MTT solution (5 mg/ml) was
added to each well of 96-well plate and incubated for
additional 4 h. The MTT solution was slowly aspired
and 100 μl of DMSO was added to dissolve the purple
color formazan crystals. The absorbance of formazan
was evaluated using Bio-Tek Synergy HT plate reader
(Bio-Tek Instruments Inc., USA) at 570 nm.
Cell viability %ð Þ ¼ Absorbance of cells exposed to samples  100%
Absorbance of untreated cells
Apoptosis Analysis
The apoptosis assay was carried out using a flow cyt-
ometer (FACS). Briefly, 5 × 105 cells were seeded in a
six-well plate and incubated for 24 h. The cells were
then treated with free CRB, PLGA NP, PCC, and FPCC
and incubated for additional 24 h. The cells were then
harvested with trypsin-EDTA, centrifuged and washed
twice with ice-cold PBS. Subsequently, binding buffer
(1×) was added to each tube. Then, 100 μl of cell sus-
pension was transferred to FACS tube and treated with
5 μl of annexin and 5 μl of 17-AAD, vortexed, and incu-
bated for 15 min. After mixing, 400 μl of binding buffer
was added to each tube and apoptosis was analyzed
using flow cytometer (Beckman Coulter, Inc., Fullerton,
CA, USA). Here, the total apoptosis includes both early
and late apoptosis.
Statistical Analysis
All data were analyzed by paired t test using SPSS 11.0
software. Differences were considered statistically signifi-
cant at P < 0.05.
Results and Discussion
Particle Size and Surface Characteristics of Nanoparticles
The mean size of different nanoparticles is presented in
Table 1. The average size of PLGA NP was 85 nm while
particle size increased to 145 nm for the deposition of
chitosan on the surface (chitosan-coated PLGA NP
(PCC)). The particle size of folic acid-conjugated PCC
NP however increased to 190 nm with a narrow size dis-
tribution. The gradual increase in the average particle
size was attributed to the deposition of additional
materials [27]. Consistently, zeta potential was checked
to confirm the formation of nanoparticles. The PLGA
has a strong negative charge around −20 mV while it
reversed to +26.5 mV for the additional of chitosan indi-
cating a firm deposition of additional mass on the poly-
mer surface. It has been reported that intracellular
uptake of nanoparticles in tumor tissue was influenced
by the size of nanoparticles [11, 12]. The optimized
nanoparticles (FPCC) in the present study are very much
suitable for the cancer targeting study. FPCC displayed
high entrapment efficiency (EE) of more than 90 % with
an effective loading of 11.85 %. It should be noted that
conjugation of folic acid did not alter the loading cap-
acity of formulated drug.
Surface Characteristics
The morphology of PCC and FPCC was evaluated by
means of TEM imaging. The chitosan-coated PLGA NP
(PCC) presented spherical-shaped particles which were
uniformly dispersed in the TEM grid (Fig. 2a, b). The
conjugation of FA did increase the overall particle size;
however, it retained the original shape of the particles.
The particles were observed to be smooth and consistent
with the DLS analysis.
In Vitro Drug Release
The drug release was carried out using dialysis method.
The release study was carried out in phosphate buffered
saline (pH 7.4) in order to simulate physiological condi-
tions. ICP-MS method was used to determine the
amount of drug released. As shown in Fig. 3, CRB from
PCC and FPCC released significantly slower compared
to that from PLGA NP. It should be noted that nearly
60 % of drug released from PLGA NP at the end of 24 h
while only 35 % of drug released from PCC and FPCC
nanosystems. The slower release of drug from PCC and
FPCC was mainly attributed to the presence of protect-
ive chitosan layer that might increase the path length of
drug. It should be noted that the presence of FA did not
alter the release rate of the drug throughout the study
period [27, 28].
Cellular Uptake Efficiency
In order to exhibit the high cytotoxic effect, the intracel-
lular concentration of drug is very important which in
turn depends on the cellular uptake efficiency of nano-
particles. The cellular uptake of PLGA, PCC, and FPCC
Table 1 Characterization of drug-loaded nanoparticles
Size (nm) Charge (mV) PDI EE (%) DL (%)
PLGA NP 85.5 ± 1.86 −20.5 ± 1.15 0.124 98.2 ± 2.35 16.5 ± 1.84
PCC NP 145.8 ± 2.1 +26.5 ± 1.65 0.168 95.2 ± 3.65 12.56 ± 1.65
FPCC NP 189.5 ± 1.8 +21.6 ± 1.19 0.198 94.6 ± 2.46 11.85 ± 1.95
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was evaluated in HeLa cells using courmarin-6 as a
fluorescent probe. The study was conducted at different
incubation time points. From the result, it can be clearly
understood that surface morphology has a great impact
on the cellular internalization capacity. One thing which
is common in all the carriers is that a typical time-
dependent cellular uptake was seen. PCC has higher cel-
lular uptake than that of PLGA NP while FPCC has
highest cellular uptake compared to any nanoparticles in
the study (Fig. 4a). It can be safely assumed that the
positively charged nanoparticle could be preferably inter-
nalized than anionic PLGA NP [29]. Evidently, enhanced
cellular uptake of FPCC was attributed to the presence
of FA on the surface of nanoparticles. It could be ex-
pected that enhanced cellular uptake of FPCC was due
to interaction of FA with the FRs-α which is overex-
pressed on the HeLa and promoted higher delivery. The
percent accumulation of FPCC in HeLa cells was
remarkably greater than other systems. These results
indicated that FPCC had a specific affinity for the can-
cerous, HeLa cells owing to ligand-receptor (FA-FR-α)
recognition.
Qualitative Cellular Uptake
Consistent with the quantitative cellular uptake, FPCC
showed a good internalization efficiency compared to
that of PCC and PLGA NP. The enhanced internaliza-
tion of FPCC was evident from the bright green fluores-
cence of cells (Fig. 4b). This difference could be a direct
consequence of surface modifications with FA while
PCC uptake was greater than that of PLGA as CS coat-
ing changes the negative surface charge to a positive
one. It has been reported that the internalization of cat-
ionic CS particles appears to occur predominantly by
adsorptive endocytosis.
Fig. 2 Transmission electron microscope (TEM) imaging of a chitosan-coated PLGA nanoparticles and b folic acid-conjugated chitosan-coated
PLGA nanoparticles
Fig. 3 In vitro release kinetics of carboplatin-loaded chitosan-coated PLGA nanoparticles (PCC) and folic acid-conjugated chitosan-coated PLGA
nanoparticles (FPCC). The release study was carried out in phosphate buffered saline (PBS) at 37 °C
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In Vitro Cytotoxicity Assay
To estimate the effectiveness of free CRB, PLGA NP,
PCC, and FPCC on killing the HeLa cancer cells, MTT
assay was performed. It can be clearly seen from the
Fig. 5 that all the formulations exhibited a clear dose-
dependent cytotoxicity in HeLa cancer cells. Especially, a
clear trend in cytotoxicity was observed. As seen, PCC
was more effective than PLGA NP while FPCC showed
a superior anticancer effect after 24 h of incubation. The
cytotoxicity potential of different formulations was con-
sistent with the cellular uptake efficiency of particles.
For example, PLGA NP has better penetrability than
that of free drug while cationic chitosan-coated formula-
tion has better internalization that plain PLGA NP. This
could be due to the presence of cationic charge on the
surface. Importantly, FPCC showed superior cytotoxic
Fig. 4 Cellular uptake analysis in cervical cancer cell (HeLa). a Quantitative cellular uptake analysis by fluorescence analysis and (b) qualitative
cellular uptake in HeLa cells using confocal laser scanning microscope (CLSM). Drug was replaced with coumarin-6 for the fluorescence experiment.
Quantitative cellular uptake was performed at different time points while qualitative experiment was performed after 2 h incubation
Fig. 5 In vitro cytotoxicity analysis of CRB, PLGA NP, PCC, and FPCC in human cervical cancer, HeLa cells. The cells were incubated with formulations
for 24 h and assayed by MTT protocol
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effect than any other formulations. The IC50 (concentra-
tion of the drug required to kill 50 % of the cells) value of
FPCC was 0.65 μg/ml while it was 1.08, 1.56, and
2.35 μg/ml for PCC, PLGA NP, and free CRB, respectively.
The selective uptake of FPCC and enhanced cytotoxicity
in HeLa cells might improve the chemotherapeutic effi-
cacy of carboplatin.
Apoptosis Assay
In the present study, apoptosis assay was performed
using Annexin-V/17-AAD staining protocol in HeLa
cancer cells. All the formulations induced a cell apop-
tosis according to their potency (Fig. 6). Significant dif-
ferences in apoptosis were observed between free CRB,
PLGA NP, PCC, and FPCC. Consistent with the cytotox-
icity assay, FPCC induced higher fraction of early as well
as late apoptosis cells. Especially, FPCC induced nearly
45 % of early apoptosis cells and more than 35 % in late
apoptosis. The superior cytotoxic effect of FPCC could
be attributed due to the higher internalization of FPCC
inside the cells (due to the surface modification of folic
acid) and continuous exposure and sustained release of
the drug for a prolonged period of time at the site of
action. Generally, apoptosis of cells is a normal physio-
logical process which plays a pivotal role on the develop-
ment of tissue organisms, morphological changes such
as cytoplasm shrinkage, chromatin condensation, DNA
fragmentation, and apoptotic body formations. Based on
the result, it can be easily interpreted that folate conju-
gation to the nanoparticle has a great impact on the
cervical cancer cell survival and could be advantageous
to the cancer treatment.
Conclusions
In summary, a unique folic acid-conjugated chitosan-
coated PLGA nanoparticle was prepared for the selective
delivery of carboplatin to the cervical cancer cells. The
particles were nanosized and spherical shaped with size
less than <200 nm. The presence of protective chitosan
layer controlled the overall release rate of CRB from
PCC and FPCC. FPCC displayed a higher cellular uptake
capacity in HeLa cells than compared to non-targeted
nanoparticles. Selective uptake of FPCC was due to
interaction of FA with the FRs-α which is overexpressed
on the HeLa and promoted active targeting. These re-
sults indicated that FPCC had a specific affinity for the
cancerous, HeLa cells owing to ligand-receptor (FA-FR-
α) recognition. Consistently, FPCC showed superior
cytotoxic effect than any other formulations. The IC50
(concentration of the drug required to kill 50 % of the
cells) value of FPCC was 0.65 μg/ml while it was 1.08,
1.56, and 2.35 μg/ml for PCC, PLGA NP, and free CRB,
respectively. Consistent with the cytotoxicity assay,
FPCC induced higher fraction of early as well as late
apoptosis cells. Especially, FPCC induced nearly 45 % of
early apoptosis cells and more than 35 % in late apop-
tosis. Therefore, we propose that folate-conjugated
nanoparticles might have potential applications in cer-
vical cancer therapy.
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